The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,415,169 in first-year total cost, median $1,529,954.
Most frequent study sections
- Special Emphasis Panel[ZAI1 MFH-M (J1)]3
Most frequent institutions
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR1
- UNIVERSITY OF PENNSYLVANIA1
- VANDERBILT UNIVERSITY MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines1U19AI174999-01 | LACY, DANA BORDEN | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $1,570,047 | ZAI1 |
| 2023 | mVACS--mRNA Vaccines for C. difficile Suppression1U19AI174998-01 | BUSHMAN, FREDERIC DWEISSMAN, DREW | UNIVERSITY OF PENNSYLVANIA, PA | $1,529,954 | ZAI1 |
| 2023 | Advancing a second generation C. difficile vaccine1U19AI174994-01 | LANG, MARK L | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $1,315,168 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.